Method Of Generating Islet Beta-Cells From Exocrine Pancreatic Cells
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention discloses an in vitro method wherein mammalian beta-cell differentiation can be induced in dedifferentiated exocrine pancreatic cells in a medium comprising ligands of the EGF receptor and the GP130 receptor, such as EGF and LIF. Insulin secreting cells, obtainable by this method, provide a means for the treatment of diabetes by islet transplantation.
-
Citations
61 Claims
-
1-44. -44. (canceled)
-
45. An in vitro method of generating insulin producing beta cells from a population comprising dedifferentiated exocrine pancreatic cells of a first mammal, said method comprising the steps of:
-
a) providing a population comprising dedifferentiated exocrine pancreatic cells in a culture medium, b) adding one or more ligands of the gp130 receptor of a second mammal and/or adding one or more ligands of the EGF receptor of a third mammal to said culture medium, c) incubating said dedifferentiated exocrine pancreatic cells in said culture medium comprising said one or more ligands of the gp130 receptor and/or said one or more ligands of the EGF receptor. - View Dependent Claims (46, 47, 48, 49, 50, 51)
-
-
52. A population of mammalian pancreatic cells comprising mammalian insulin producing beta cells obtainable by an in vitro method of generating insulin producing beta cells from a population comprising dedifferentiated exocrine pancreatic cells of a first mammal, said method comprising the steps of:
-
a) providing a population comprising dedifferentiated exocrine pancreatic cells in a culture medium, b) adding one or more ligands of the gp130 receptor of a second mammal and/or adding one or more ligands of the EGF receptor of a third mammal to said culture medium, c) incubating said dedifferentiated exocrine pancreatic cells in said culture medium comprising said one or more ligands of the gp130 receptor and/or said one or more ligands of the EGF receptor. - View Dependent Claims (53, 54, 55, 56, 61)
-
-
57. A method of prevention or treatment of diabetes type 1 or type 2 comprising administration of a therapeutically effective amount of a combination of a human or humanised ligand of a EGF receptor, and a human or humanised ligand of the gp130 receptor.
- 58. A method of prevention or treatment of diabetes type 1 or type 2 comprising administration of a therapeutically effective amount of a human or humanised ligand of the gp130 receptor.
Specification